article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 As of October 2023, 62.93

Safety 110
article thumbnail

UroMems Announces First-Ever Smart Artificial Urinary Sphincter Implant in a Female Patient

Legacy MEDSearch

UroMems , a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-ever implant of the UroActive smart, automated artificial urinary sphincter (AUS) in a female patient. Food and Drug Administration).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Voice is Becoming the Loudest Tool in the Exam Room

PM360

The line from the 2011 Pixar “Cars” sequel (trust me, as a parent of two, I have seen it countless times) points to the practical implication for voice technology. While this sort of innovation might not be a surprise in the automotive category, its breadth of functional benefits for patients and healthcare providers (HCPs) might be.

article thumbnail

Patient centricity 101: How to create content that REALLY communicates

pharmaphorum

According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

1 The regulation is the culmination of a long debate between European Union (EU) Member States and health sector stakeholders, triggered by joint actions such as European Network for Health Technology Assessment (EUnetHTA) and formalised through the European Commission (EC)’s proposal in January 2018. governmental healthcare organisations.

article thumbnail

Are timely access and robust safety mutually exclusive?

pharmaphorum

Cancer patients in Europe wait an average of almost eight months longer for access to breakthrough medications than their American counterparts. The balance between shortening approval times, allowing oncology patients to receive therapies earlier, and ensuring treatments are safe and efficacious is delicate.”.

Safety 95
article thumbnail

Top 12 Healthcare Technology Start-ups To Know

Medico Reach

Now, besides maintaining patient records and facilitating seamless test procedures, the organization also: Assists pharmaceutical and biotech companies in drug development Guides patients in finding optimal cancer therapy solutions Helps medical professionals make informed decisions through clinical studies. Flatiron Health.